ARGX
argenx NV ADR
NASDAQ: ARGX · HEALTHCARE · BIOTECHNOLOGY
$776.02
+0.13% today
Updated 2026-04-29
Market cap
$48.85B
P/E ratio
40.03
P/S ratio
11.53x
EPS (TTM)
$19.53
Dividend yield
—
52W range
$510 – $935
Volume
0.3M
argenx NV ADR (ARGX) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
6 of 8
Last 8 quarters
Avg EPS surprise
+60.4%
Last 4 quarters
Revenue YoY growth
+78.7%
Most recent quarter
EPS YoY growth
+853.6%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-3.3%
Last 2 reports
Positive reaction rate
0%
0 of 2 quarters
Largest single-day move
-6.1%
2026-02-26
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-26 | $6.79 | +14.2% | $816.95 | $766.92 | -6.1% |
| 2025-10-30 | $5.18 | +16.7% | $821.97 | $818.50 | -0.4% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $5.95 | $6.79 | +14.2% | $2.41B | +78.7% |
| 2025-09-30 | $4.44 | $5.18 | +16.7% | $1.13B | +96.6% |
| 2025-06-30 | $-0.99 | $3.26 | +429.0% | $947.96M | +5.1% |
| 2025-03-31 | $2.05 | $2.27 | +10.6% | $790.68M | +97.2% |
| 2024-12-31 | $1.70 | $0.71 | -58.0% | $1.35B | +77.7% |
| 2024-09-30 | $0.03 | $1.39 | +4533.3% | $573.24M | +73.8% |
| 2024-06-30 | $-0.98 | $0.45 | +145.9% | $901.94M | +92.6% |
| 2024-03-31 | $-0.86 | $-1.04 | -20.9% | $401.00M | — |
| 2023-12-31 | $-1.70 | $-1.68 | +1.2% | $757.68M | — |
| 2023-09-30 | $-1.54 | $-1.25 | +18.8% | $329.79M | — |
| 2023-06-30 | $-1.73 | $-1.69 | +2.3% | $468.20M | — |
Analyst EPS and revenue estimates for upcoming years
| Period | EPS estimate | Revenue estimate | Revenue growth | Analysts | Confidence |
|---|---|---|---|---|---|
| 2026 (E) | $27.90 | $6.1B | +43.2% | 19 | high |
| 2027 (E) | $38.50 | $8.4B | +38.4% | 19 | high |
| 2029 (E) | $62.00 | $14.1B | +25.9% | 19 | medium |
| 2030 (E) | $75.50 | $17.3B | +22.7% | 19 | medium |
Frequently asked questions
Has argenx NV ADR beaten earnings estimates?
argenx NV ADR has beaten Wall Street EPS estimates in 6 of its last 8 quarterly reports, with an average EPS surprise of +60.4% over the last 4 quarters.
How does ARGX stock react to earnings?
ARGX stock has moved an average of -3.3% in the trading day following earnings over its last 2 reports, with positive reactions in 0% of those quarters.
What is argenx NV ADR's revenue growth rate?
argenx NV ADR reported year-over-year revenue growth of +78.7% in its most recent quarter, with EPS growing +853.6% year-over-year.
What is the expected EPS for ARGX in 2026?
Analysts expect argenx NV ADR to report EPS of $27.90 for fiscal year 2026, on revenue of $6.1B, based on estimates from 19 analysts.